Drug intelligence / Profile preview

BNSO-2

Development stage: Preclinical
Lead developer: BNS Ophthalmics
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravitreal

Overview

BNSO-2 is an investigational intravitreal steroid developed by BNS Ophthalmics, a joint venture between RAFARM and BioNanoSim. It is designed for the treatment of macular edema and age-related macular degeneration, leveraging BioNanoSim's proprietary nanotechnology platform for its formulation and delivery.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on BNSO-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNSO-2.

Explore the full profile